Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmunityBio Inc. is conducting an open-label, Phase 2 study titled ‘Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma.’ The study aims to evaluate the efficacy of a combination therapy involving CD19t-haNK and N-803 with Rituximab in treating relapsed or refractory B-cell Non-Hodgkin Lymphoma. This research is significant as it explores novel immunotherapy approaches for challenging lymphoma cases.
The study tests two main interventions: CD19t-haNK, administered intravenously, and N-803, a subcutaneous IL-15 superagonist. CD19t-haNK targets CD19-expressing B-cell malignancies, while N-803 enhances natural killer and CD8+ T cell activity, aiming to improve immune response against cancer cells.
This interventional study follows a single-group assignment model without masking, focusing on treatment as the primary purpose. The open-label design allows all participants to receive the investigational therapy, providing clear insights into its effects.
The study is set to begin on August 11, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was also on August 11, 2025, indicating the study’s preparatory phase.
The study’s progress could influence ImmunityBio’s stock performance and investor sentiment, especially if the results show promise in treating difficult lymphoma cases. This could position the company favorably against competitors in the oncology sector.
The study is ongoing, and further details are available on the ClinicalTrials portal.